Weekly Recap: Orladeyo pellets cleared and guidance kept, expenses cut
BioCryst Pharmaceuticals (NASDAQ:BCRX) resolved a pediatric Orladeyo manufacturing delay with pellets due early August while preserving FY revenue guidance and trimming 2026 operating expense outlook as it winds down Birmingham; Cantor raised its price target and the company granted inducement equi…